应用蛋白芯片-飞行质谱技术筛选宫颈癌血清差异蛋白质

Proteinchip-flight mass spectrometry for screening differentially expressed proteins in the serum of cervical cancer patients

目的筛选宫颈癌患者与健康女性血清之间的差异蛋白质,寻找宫颈癌早期诊断的生物学指标。方法采用表面增强激光解吸离子化飞行时间质谱仪(SELDI-TOF-MS)和弱阳离子结合芯片(CM10),检测24例宫颈鳞状细胞癌及25例年龄相匹配的健康女性的血清蛋白质,获得相应的指纹图谱,经生物信息学分析,筛选出一组有分类意义的差异蛋白质。结果宫颈癌与正常对照组比较,在分子量1.0～20kDa范围内,共有52种蛋白质质谱峰的差异有统计学意义(P<0.05),其中质荷比(M/Z)为4173.77、5903.09、6087.12、10716.9、6109.61、3397.41,在宫颈癌组的含量明显低于正常对照组(P<10-5);由软件自动建立2个诊断树模型,其一以单个差异蛋白质4173.77(M/Z)作为分类变量,其诊断宫颈癌的敏感性为75.0%,特异性为96.0%;其二以M/Z为5335.81、7562.99、9287.89的3个差异蛋白质建立分类模型,其诊断宫颈癌的敏感性为91.67%,特异性为96.0%。结论宫颈癌患者与健康正常女性血清蛋白质的表达存在差异,其中6个蛋白质差异非常显著,有可能作为宫颈癌早期诊断的生物学指标;同时以差异蛋白质所建立的诊断树模型,有助于宫颈癌患者的早期筛查。

Objective To identify the differentially expressed proteins in the serum of patients with cervical cancer for use as the biomarkers for early diagnosis of cervical cancer. Methods Surface-enhanced laser desorption/ionization time of flight mass spectrometry （SELDI-TOF-MS） with weak cationic chips （CM10） was used to examine the serum samples of 24 patients with cervical squamous cell carcinoma and 25 age-matched healthy women. The protein fingerprints were obtained, and bioinformatic analysis was performed to identify the differentially expressed proteins in the serum of the patients. Results Fifty-two differentially expressed proteins were detected in the serum of cervical cancer patients （P〈I05）, among which 6 proteins with mass/charge ratio of 4173.77, 5903.09, 6087.12, 10716.9, 6109.61 and 3397.41, respectively, showed lowered expression in the serum of cervical cancer patients. Two diagnostic models for cervical cancer were generated using software, including one consisting of the 4173.77（M/Z） protein with the diagnostic specificity of 96% and sensitivity of 75% for cervical cancer and the other consisting of 3 proteins at 5335.81 （M/Z）, 7562.99（M/Z）, and 9287.89（M/Z） with specificity of 91.67% and sensitivity of 96.0%. Conclusion Cervical cancer patients show different serum protein expression profile from healthy women. The 6 differential proteins identified may serve as specific serum biomarkers in close relation to the origin and progression of cervical cancer.